CDTI Innovation and Asabys Partners invest in the startup Nuage Therapeutics
CDTI Innovación, through the Innvierte program, together with Asabys Partners, through the Sabadell Asabys Health Innovation Investments fund, have reached an agreement with Nuage Therapeutics partners to invest in the startup. The contribution committed by the CDTI is 450,000 euros. With this injection of capital, the biotech company, based in the Barcelona Science Park, wants to advance in the development of its technology to bring its first therapeutic product closer to cancer patients.
Nuage Tx was born in 2021 as a spin-off of the Institute for Research in Biomedicine (IRB Barcelona) and the Catalan Institution for Research and Advanced Studies (ICREA), promoted by Dr. Xavier Salvatella and Dr. Mateusz Biesaga from IRB Barcelona; Dr. Denes Hnisz, from the Max Planck Institute for Molecular Genetics in Berlin; and Dra. Judit Anido, scientist and entrepreneur with experience in the creation and development of biotechnology companies.
The company is developing new drugs aimed at therapeutic targets previously considered unapproachable by the pharmaceutical industry due to their lack of structure. These therapeutic targets are known as Intrinsically Disordered Proteins (PIDs) and have been associated on numerous occasions with diseases with unmet medical needs, such as cancer.
The first Nuage Tx program aims to develop, through its technology, a new potent and selective drug aimed at patients with certain types of prostate cancer.